Cyprotex launches screening service to study metabolic drug interactions

By E. Janene Geiss

Philadelphia, July 6 - Cyprotex announced Thursday the launch of its new screening service, designed to help drug discovery teams identify compounds that are mechanism-based inhibitors of Cytochrome P450 (CYP450).

The inhibition of human CYP450s is one of the most common mechanisms that can lead to drug-drug interactions, according to a company news release.

Metabolic drug-drug interactions, following the co-administration of drugs, can result in either reduced efficacy or increased toxicity, officials said.

Screening for mechanism-based inhibition of CYP450 earlier in the drug discovery process enables researchers to determine and advance only the compounds that avoid such liabilities, thereby reducing the possibility of costly late-stage failures.

Cyprotex's Cloe screen mechanism-based inhibition assay identifies compounds that are inhibitors of the CYP3A4 isoform, one of the most abundant human CYP450s.

By using mass spectrometry as an end-point coupled with Cyprotex's state-of-the-art automation capabilities, the Cloe screen mechanism-based inhibition assay is a high-quality and cost-effective method, which offers rapid turnaround, officials said.

Further mechanism based inhibition assays, using other industry recommended probe substrates, are currently in development at Cyprotex, officials said.

Cyprotex, based in Cheshire, England, provides technology to evaluate absorption, distribution, metabolism and elimination, toxicity and pharmacokinetic properties of potential drugs early in the discovery process.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.